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Abstract
Objective: It was aimed to review the literature and make a meta-analysis of the trials on both
upfront, switching, and sequencing anastrozole in the adjuvant treatment of early breast cancer.
Methods: The PubMed, ClinicalTrials.gov and Cochrane databases were systematically reviewed
for randomized-controlled trials comparing anastrozole with tamoxifen in the adjuvant treatment
of early breast cancer.
Results: The combined hazard rate of 4 trials for event-free survival (EFS) was 0.77 (95%CI: 0.70–
0.85) (P < 0.0001) for patients treated with anastrozole compared with tamoxifen. In the second
analysis in which only ITA, ABCSG 8, and ARNO 95 trials were included and ATAC (upfront trial)
was excluded, combined hazard rate for EFS was 0.64 (95%CI: 0.52–0.79) (P < 0.0001). In the third
analysis including hazard rate for recurrence-free survival (excluding non-disease related deaths) of
estrogen receptor-positive patients for ATAC trial and hazard rate for EFS of all patients for the
rest of the trials, combined hazard rate was 0.73 (95%CI: 0.65–0.81) (P < 0.0001).
Conclusion:  Anastrozole appears to have superior efficacy than tamoxifen in the adjuvant
hormonal treatment of early breast cancer. Until further clinical evidence comes up, aromatase
inhibitors should be the initial hormonal therapy in postmenopausal early breast cancer patients
and switching should only be considered for patients who are currently receiving tamoxifen.
Introduction
The standard treatment of early breast cancer is surgery,
with or without radiotherapy and chemotherapy, fol-
lowed by hormonal therapy for women with hormone
receptor-positive tumors. Although 5 years of tamoxifen
has been the mainstay of adjuvant hormonal therapy for
more than 20 years [1], tamoxifen is associated with treat-
ment resistance [2] and some serious adverse events, like
endometrial carcinoma and thromboembolic complica-
tions [3]. On the other hand, recent findings from large
randomized trials have shown that anastrozole, a third
generation aromatase inhibitor, has higher efficacy in
terms of lower recurrence rates and better safety profile
than tamoxifen as adjuvant therapy in early breast cancer
[4-9]. Therefore, it is now widely accepted that anastro-
zole has a key role in management of postmenopausal
women with early breast cancer. The American Society of
Clinical Oncology Technology Assessment Panel recom-
mends that 5 years of tamoxifen alone is no longer the
best adjuvant treatment for postmenopausal patients with
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hormone-sensitive early breast cancer, and that optimal
treatment should include an aromatase inhibitor to
reduce the risk of tumor recurrence [10].
Although there are several studies on the advantages of
anastrozole over tamoxifen as adjuvant hormonal therapy
of hormone-sensitive early breast cancer, the timing and
duration of anastrozole treatment remains in question.
The Arimidex, Tamoxifen Alone or in Combination
(ATAC) trial used an "upfront approach" where anastro-
zole was started as the first-line hormonal therapy [4,5,9],
whereas other trials have used a "switching approach"
where patients already receiving tamoxifen therapy for
several years were randomized to continuing tamoxifen or
switching to anastrozole [6-8]. A recent meta-analysis
using individual data from 3 switch trials have demon-
strated a statistically significant survival benefit in addi-
tion to disease- and event-free survival (DFS and EFS,
respectively) rates [11]. In a third approach, anastrozole
was prospectively sequenced after several years of
tamoxifen treatment for newly diagnosed patients
(sequencing approach) [12]. All approaches have shown
a superior efficacy and safety of anastrozole over
tamoxifen.
To address the overall impact of all three approaches, I
sytematically reviewed the literature and did a meta-anal-
ysis of randomized trials on upfront, switching, and
sequencing schedules of anastrozole adjuvant treatment
in early breast cancer.
Four clinical trials were included in this meta-analysis:
ATAC [4], Italian Tamoxifen Anastrozole (ITA) [8], Aus-
trian Breast and Colorectal Cancer Study Group (ABCSG
8) [12], and Arimidex-Nolvadex (ARNO 95) [13] trials.
The differences between upfront, switching, and sequenc-
ing approaches were discussed in the light of the findings
of this analysis and the literature.
Materials and methods
Search strategy and selection criteria for trials
Systematic literature searches of PubMed, ClinicalTri-
als.gov and Cochrane databases were performed by using
the keywords anastrozole (or Arimidex) and breast cancer.
There was no date restriction, but the research was
restricted to trials published in the English language. I
reviewed the titles and abstracts of all the articles retrieved
by this search. I considered randomized controlled trials
to be eligible if they compared anastrozole with another
agent in the adjuvant treatment of early breast cancer,
with no restriction of study phase and regardless of doses
or schedules. I didn't include dose escalation studies or
single arm studies. When there were multiple records
related to the same study, I extracted end point data from
the report with the longest follow-up.
There were 3 recent meta-analyses, 2 on advanced disease
[14,15] and 1 on early breast cancer [11]. Meta-analysis
on early breast cancer was performed by combining the
original individual data of 3 published studies [6-8] and
did not include the results of the ATAC trial [4].
The conduct and reporting of meta-analysis was per-
formed in accordance with the Quality of Reporting of
Meta-analyses (QUOROM) statement [16].
Data extraction and end points
I extracted the following data from each eligible trial:
authors' names, journal, date of publication, number of
patients randomized to each arm (ITT population) and
analyzed per arm, median age of patients, menopausal
and hormone receptor status, and treatment schedule and
doses. I also recorded if there was a proper mode of rand-
omization and allocation method described in the publi-
cation, median follow-up, median survival, drop-out rates
and adverse events per arm, and definitions of EFS, DFS,
and recurrence free survival (RFS). Hazard rates (HR) and
confidence intervals (CI) for these end points were also
extracted from the publications.
Quality of trials were assessed based on the reporting of
method of randomization and allocation concealment,
comparability of baseline treatment groups, reasons for
drop-outs and if there was any evidence of differential
drop-outs between treatment arms.
Statistical analyses
HR from Cox proportional models reported in the origi-
nal publications comparing anastrozole and comparator
treatment was combined. The natural logarithms of the
HR were combined using general variance models, and
utilizing inverse variance weights[17]. Between-study het-
erogeneity was assessed using chi-square based Q statistic.
Data were combined by using both fixed- and random-
effect models and fixed-effects model results were
reported when both results were nearly identical in addi-
tion to a non-significant heterogeneity test (P > 0.10). For
our primary analysis EFS rates from ABCSG 8, ARNO 95
and ITA trials were combined but RFS rates were used
from ATAC trial because EFS rates weren't reported and
RFS was the most similar end point to other trials in terms
of exclusion of recurrence-free deaths. A group of sensitiv-
ity analyses were made by excluding ATAC trial from our
analyses and also by analysing only hormone receptor-
positive patient groups.
Publication bias could not be assessed due to small
number of studies included in the analysis. All analyses
were performed using STATA version 9 (College Station,
TX, USA).Trials 2008, 9:47 http://www.trialsjournal.com/content/9/1/47
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Results
I identifed 635 potential studies on anastrozole treatment
in breast cancer during initial literature search (Figure. 1).
Each study was evaluated for inclusion in the meta-analy-
sis. Of these 635 studies, most were not clinical trials, but
reviews and short-term laboratory studies. There were 9
randomized-controlled trials of anastrozole in patients
with early breast cancer. For all these 9 trials, patients in
the control group were treated with tamoxifen. Of these 9
trials, 2 were on neoadjuvant treatment and did not
include clinical end points, 1 was a publication combin-
ing the results of previously published 2 studies [18]. The
remaining 6 publications were the results of 4 different
studies, which are ATAC [4], ITA [8], ABCSG 8 [12], and
ARNO 95 [13] trials. These four trials were included in the
meta-analysis.
Demographic and baseline cancer characteristics of
patients and treatment regimens were similar across ITA,
ABCSG 8, and ARNO 95 trials. In all these 3 trials, nearly
all of the patients were estrogen receptor-positive and had
received 2–3 years of tamoxifen before randomization to
study groups. For both ITA and ARNO 95 trials, patients
who had completed 2–3 years of adjuvant tamoxifen
treatment and were relapse-free were randomized to
either continue tamoxifen (20 or 30 mg/day) or switch to
anastrozole (1 mg/day) for the remainder of their treat-
ment (5 years in total). For ABCSG 8 trial, anastrozole vs.
tamoxifen was prospectively sequenced after 2 years of
tamoxifen treatment for newly diagnosed patients. One
year after switching or sequencing, patients were clinically
evaluated every 3 months in the ABCSG 8 and ITA trials;
and then every 6 months or year for all 3 trials. All three
studies assessed local and distant recurrence, contralateral
breast cancers, and all deaths (deaths following recurrence
and deaths without recurrence). The patient characteris-
tics and treatment regimen were different for ATAC trial
than the other 3 trials. ATAC trial compared 5 years of
anastrozole with tamoxifen alone, or combination of the
two drugs, as adjuvant therapy in postmenopausal
women with localized breast cancer after surgery and
chemotherapy (if applicable). Patients did not receive any
hormonal treatment before randomization. Hormone
receptor status for the 14% of study population was
unknown at the time of randomization. It has the longest
median follow-up time and highest sample size of all 4 tri-
als (Table 1). Clinical status of patients was evaluated at 3
months, and 6 months; thereafter assessments were
scheduled every 6 months up to 5 years. The summary of
4 trials is given in Table 1.
All studies included in this meta-analysis reported a sig-
nificant improvement in EFS with anastrozole compared
with tamoxifen (Table 1, Figure. 2).
Results of our primary analysis, where HR for RFS for
ATAC trial and HRs for EFS for other trials were included
in the model, showed that using anastrozole as an adju-
vant treatment was statistically significantly associated
with increased EFS (HR: 0.77, 95%CI: 0.70–0.85, P  <
0.0001) (Figure. 2). In a second analysis in which only
switching and one sequencing trial were included and
ATAC was excluded, combined HR for EFS was 0.64
(95%CI: 0.52–0.79, P < 0.0001) (Figure. 3). This differ-
ence between two analyses in favor of switching and
sequencing trials was an expected finding due to the dif-
ferences between upfront (ATAC) and other 3 trials in
terms of patient population and study design as discussed
in detail later.
Since in ATAC trial hormone receptor status for the 14%
of study population was unknown at the time of randomi-
zation, the ratio of patients with positive estrogen recep-
tors was lower than that of patients in switching and
sequencing trials, where almost all of the patients were
estrogen receptor positive (Table 1). Therefore, to main-
tain more similarity between trials, a third analysis was
done by including HR for RFS (excluding deaths) of estro-
gen receptor-positive patients for ATAC trial and HRs for
EFS of all patients for the other 3 the trials. The HR for RFS
of estrogen receptor-positive patients for ATAC trial was
0.76 (95%CI: 0.67–0.87), P < 0.0001) and combined HR
was found to be 0.73 (95%CI: 0.65–0.81), P < 0.0001)
(Figure. 4).
In all 3 models, heterogeneity test revealed non-signifi-
cant results.
Discussion
The current treatment strategy for breast cancer, which is
the most common cancer among women worldwide [19],
includes the adjuvant use of hormonal therapy for hor-
mone receptor-positive tumors after surgery with or with-
out radiotherapy and chemotherapy [20]. Aromatase
inhibitors have been shown to be more effective and safer
than tamoxifen for adjuvant hormonal therapy of both
early and advanced stage breast cancer in postmenopausal
women [14,15,21-25]. Among aromatase inhibitors,
anastrozole is specific to aromatase and has no significant
interactions with other enzymes. Therefore, anastrozole is
emerging as one of the new standards for the adjuvant
treatment of hormone-sensitive early breast cancer [26].
The advantages of anastrozole over tamoxifen as an adju-
vant hormonal therapy are now widely accepted, but the
optimal duration of treatment and whether tamoxifen
needs to be incorporated into the treatment strategy at
some point remain unclear.
In this meta-analysis, the results of 4 trials were analyzed
comparing anastrozole and tamoxifen in the adjuvantTrials 2008, 9:47 http://www.trialsjournal.com/content/9/1/47
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Flow diagram for identification of trials for meta-analysis Figure 1
Flow diagram for identification of trials for meta-analysis.Trials 2008, 9:47 http://www.trialsjournal.com/content/9/1/47
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treatment of early breast cancer – ATAC, ITA, ABCSG 8,
and ARNO 95. It was found that the combined HR for EFS
was 0.77 (0.70–0.85) when all 4 trials were included in
the analysis, 0.64 (0.52–0.79) when ATAC the only
upfront trial was excluded, and 0.73 (0.65–0.81) when
HR for RFS of estrogen receptor-positive patients in ATAC
trial was included in the analysis.
In the trials comparing anastrozole and tamoxifen, anas-
trozole was either used as initial therapy (upfront
Table 1: Summary of trials included in meta-analysis
Trial ATAC [4-6] ITA [7,8] ABCSG trial
 8 [9,12]
ARNO 95
 trial [9,13]
Study design Multicenter, randomized Multicenter,
randomized
Multicenter,
randomized
Multicenter,
randomized
Patients Postmenopausal, receptor 
status +/unknown
Postmenopausal, estrogen receptor (+), received
2–3 years of tamoxifen
Sample size 9366 448 2529 979
Median follow-up (months) 68 64 31 30
Treatment regimen Upfronta Switchingb Sequencingc Switchingb
Estrogen receptor statusd
Positive 83.7% 91.0% 99.0% 97.1%
Negative 8.3% 1.0% 1.0% -
Unknown 8.0% 8.0% - 2.9%
Hazard ratios for
event free survival 
 (95% CI)
All patients: 0.81 (0.73–0.91)
ER positive patients: 0.76 (0.67–0.87)
0.57 (0.38–0.85) 0.68 (0.49–0.91) 0.66 (0.44–1.00)
aInitial treatment with anastrozole or tamoxifen alone or in combination up to 5 years
bSwitching to anastrozole after 2–3 tamoxifen vs. continued tamoxifen for 5 years
cSequencing prospectively to anastrozole vs. tamoxifen after 2 years of tamoxifen treatment
dFor patients in anastrozole arm
Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which all 4 trials were included Figure 2
Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which all 4 trials were 
included. aFor ATAC trial, HR for recurrence free survival was included in the model. Test for heterogeneity (Q) = 4.128 (P 
= 0.248). HR: hazard rate, CI: confidence interval.Trials 2008, 9:47 http://www.trialsjournal.com/content/9/1/47
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Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which ATAC trial was excluded Figure 3
Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which ATAC trial was 
excluded. Test for heterogeneity (Q) = 0.490 (P = 0.783). HR: hazard rate, CI: confidence interval.
Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which all 4 trials were included Figure 4
Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which all 4 trials were 
included.aFor ATAC trial, HR for recurrence free survival of estrogen receptor positive patients was included in the model. 
Test for heterogeneity (Q) = 2.244 (P = 0.523). HR: hazard rate, CI: confidence interval.Trials 2008, 9:47 http://www.trialsjournal.com/content/9/1/47
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approach) [4,5,9] or adjuvant therapy was switched to
anastrozole in patients who had already received several
years of tamoxifen treatment (switching approach) [6-8]
or anastrozole was prospectively sequenced after several
years of tamoxifen treatment for newly diagnosed patients
(sequencing approach) [12] or extended adjuvant therapy
with anastrozole after 5 years of tamoxifen treatment
(extended treatment) [27]. Since the characteristics and
disease stages of study populations were very different in
these trials, it is not possible to choose the best treatment
strategy just by comparing the results of these studies. The
results of switching [6-8] studies appear to be better than
that of the ATAC trial with the upfront approach [4,5,9].
But in the ATAC trial, hormone status for 14% of rand-
omized patients was not known initially, patients were
followed from the beginning of adjuvant treatment, and
the data of all patients including those with less favorable
prognoses were analyzed [4,5,9]. Another possible expla-
nation for these findings lies in the fact that the switching
trials – ITA and ARNO 95 – were performed on patients
who were receiving tamoxifen for 2 or 3 years and who
had no evidence of relapse. This patient population, by
definition, excludes those who had relapsed during the
early years of follow up, i.e., those with a less favorable
prognosis were already eliminated from the cohort. Fur-
thermore, this is the period when patients with worse
prognosis (susceptible patients) are most likely to develop
an event such as local or distant recurrences. This is a very
well-known phenomenon in epidemiology when survival
rates are not constant over time and is sometimes called
"attrition of susceptibles" [6-8]. Therefore, although
switching approach appears to be relatively more effective
at first glance, it should not be taken as evidence for that
all patients should receive several years of tamoxifen
before switching to anastrozole.
It is also very important to interpret the results of switch-
ing and sequencing trials properly since the same problem
of "attrition of susceptibles" appears in this comparison,
too. Although study designs look similar, there is a
remarkable difference between the two approaches. In the
switching approach, adjuvant therapy is switched to anas-
trozole in patients already under tamoxifen treatment for
several years [6-8]. But in the sequencing approach, anas-
trozole is prospectively sequenced after several years of
tamoxifen treatment for newly diagnosed patients [12].
Therefore in the sequencing approach, patients are fol-
lowed from the beginning of adjuvant treatment and all
recurrences are taken into account. In contrast, the switch-
ing trials may comprise a patient population with a better
prognosis, as explained above.
It must be noted that ABCSG 8 trial was initiated as a
sequencing trial, involving upfront randomization to
tamoxifen or anastrozole after 2 years of tamoxifen treat-
ment [12]. However, in the final report, the first two years
of follow-up and patients who relapsed, died or discontin-
ued treatment were discarded and the study was trans-
formed into a switch trial. This way, the design was similar
to that of ARNO 95 and results could be combined into a
single report [6]. However, this report states that out of the
3901 patients who were initially randomised, only 2262
were eligible for the combined analysis. Twenty-three
(0.6%) of the ineligible patients died of causes other than
breast cancer, 53 (1.4%) breast cancer-related events were
encountered, 44 (1.1%) secondary carcinomas emerged
and 275 (7.0%) patients had to discontinue tamoxifen for
other reasons. The exclusion of these patients has, at least
in part, contributed to a seemingly more favorable out-
come with the switch regimen. In the combined analysis
of ABCSG 8 and ARNO 95 trials in which recurrences
before sequencing in ABCSG 8 trial were excluded in anal-
ysis, HR for EFS was found to be 0.60 (0.44–0.81, P =
0.0009), despite the higher HR observed in ARNO 95 (HR
= 0.66 [0.44–0.99]) [6]. When ABCSG 8 was reported as a
sequencing trial, the HR was slightly higher (HR = 0.76 [P
= 0.068]) [12].
Since different treatment strategies of anastrozole have
not been compared in a single clinical study, statistical
modeling methods were used to define the best strategy
[28-30]. Two main models were reported by Burstein et al.
[30] and Cuzick et al. [28,29]. The results from models
depend on assumptions and end points, therefore conclu-
sions may differ. The model of Burstein et al. found that
switching from tamoxifen to an aromatase inhibitor at 2.5
years yielded superior 10-year DFS than treatment with
either tamoxifen or aromatase inhibitor treatment alone.
In a further analysis, this model also suggested that
switching from tamoxifen to an aromatase inhibitor after
2 years seems superior for estrogen and progesterone
receptor-positive tumors, whereas 5 year treatment with
an aromatase inhibitor may be superior for patients with
estrogen positive and progesterone negative tumors [30].
Similar results were obtained in a model by Hilsenbeck
and Osborne [31]. But the model by Cuzick et al. suggests
that using an aromatase inhibitor as initial adjuvant ther-
apy is a better option than switching to an aromatase
inhibitor after 2 years of tamoxifen [28,29]. The recent
model by Cuzick et al. has some advantages over the
model by Burstein et al. which include homogeneous end
points, time-dependent recurrence rates, and considera-
tion of carry-over effect, clinical importance of early and
late recurrences, and biological interactions [28,29].
Therefore Cuzick model appears more realistic than
Burstein model.
In a meta-analysis combining the data of these 3 switch-
ing trials, patients who switched to anastrozole had signif-
icant improvement in EFS (HR 0.55 [0.42–0.71]; P  <Trials 2008, 9:47 http://www.trialsjournal.com/content/9/1/47
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0.0001) over those who remained on tamoxifen [11]. Due
to the above-mentioned reasons, the HR for EFS in the
ATAC trial was 0.79 (0.70–0.90, P = 0.0005), which was
higher than those of each and combined data of switching
trials [4]. Therefore, when ATAC data were included, the
combined HR for EFS increased to 0.77 (0.70–0.85, P <
0.0001) when it was 0.64 (0.52–0.79, P < 0.0001) for the
switching and sequencing trials in our analysis. Although
heterogeneity test between analyzed trials revealed non-
significant results for both analyses, heterogeneity was
much higher in the analysis when ATAC trial was
included. This may be attributed to the differences of
ATAC trial from the other three trials in terms of the study
design and population. To decrease the heterogeneity
between the trials, a third analysis was made by including
HR for RFS (excluding non-breast cancer related deaths
before recurrence) of estrogen receptor-positive patients
for ATAC trial and HR for EFS of all patients for the rest of
the trials. In this analysis, there was remarkably less heter-
ogeneity between trials: results of random and fixed
effects models were exactly the same. The combined HR of
this analysis was 0.73 (0.65–0.81, P < 0.0001), which was
closer to the combined HR of analysis which included
ITA, ARNO-95 and ABCSG-8.
This meta-analysis is important in terms of combining the
results of upfront, switching, and sequencing approaches
for anastrozole adjuvant treatment in early breast cancer.
Our results show that anastrozole treatment improves EFS
significantly, when compared to tamoxifen irrespective of
the treatment approach used.
The main limitation of our meta-analysis is the low
number of trials included in the analysis. To make a defin-
itive conclusion on the optimal strategy of anastrozole
adjuvant treatment in early breast cancer, trials comparing
different treatment approaches – upfront, switching,
sequencing, and extended treatment – would be highly
desirable.
Conclusion
As a conclusion, anastrozole appears to have superior effi-
cacy than tamoxifen in the adjuvant hormonal treatment
of early breast cancer. The question of giving anastrozole
upfront or after several years of tamoxifen treatment
remains open, as it is not possible to make any direct com-
parisons. However, it appears unlikely that giving
tamoxifen, an agent that has inferior activity both in the
adjuvant and metastatic setting, as first line treatment
would be more effective than starting with anastrozole.
This concept is also supported by several mathematical
models. It is thought that, until further clinical evidence
comes up, aromatase inhibitors should be the initial hor-
monal therapy in postmenopausal early breast cancer
patients. Switching should only be considered for patients
who are currently receiving tamoxifen. With the current
trends, this patient population should be expected to
decrease in size during the years to come, with the rare
exception of premenopausal patients who become post-
menopausal during tamoxifen treatment. The introduc-
tion of tamoxifen or another estrogen antagonist after the
completion of aromatase inhibitor therapy may be an
interesting research topic.
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